E. Shalit

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

R. Califf, E. Topol, P. Armstrong, 1998, Journal of the American College of Cardiology.

Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.

B. Groves, D. Stewart, R. Barst, 1999, Circulation.

Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.

R. Barst, A. Hirsch, D. Langleben, 2004, Chest.